Main content area

Acanthomatous ameloblastoma in dogs treated with intralesional bleomycin

Kelly, J.M., Belding, B.A., Schaefer, A.K.
Veterinary and comparative oncology 2010 v.8 no.2 pp. 81-86
infection, drug therapy, lesions (animal), animal injuries, neoplasms, dog diseases, gingiva, dogs, drug toxicity, antineoplastic agents, drug injection, adverse effects, swelling (physiological)
Acanthomatous ameloblastoma (AA) is a benign gingival tumour that often invades bone. This retrospective study evaluated the efficacy of intralesional (IL) bleomycin as a treatment for AA. Six dogs received weekly or bimonthly IL bleomycin injections (dose range, 10-20 U m⁻²). A seventh dog presented with advanced, nonresectable AA was treated palliatively. One to sixteen treatments were administered (median, 5). Six of the seven dogs had a complete response within 4 months from initial IL injection (median, 1.5 months), whereas the palliative case had approximately 25% decrease in tumour volume 14 days from initial injection. Local recurrence was not observed during the study period, with a median follow-up time of 842 days. Adverse effects were limited to wound formation with bone exposure (n = 4), mild tissue reactions (n = 3), local swelling (n = 2) and local infection (n = 1). The conclusions of this study show IL bleomycin is an effective treatment for canines with AA.